| Literature DB >> 32518612 |
Barış Karabulut1, Nazmiye Dönmez2, Ceren Canbey Göret3, Cafer Ataş1, Özlem Kuzu1.
Abstract
AIM: There is an increasing interest in the application of BioACTIVE materials to achieve hard tissue formation and maintain pulp vitality. Mineral trioxide aggregate (MTA) and Biodentine® are BioACTIVE materials used for pulp capping. Recently, dental researchers have produced BioACTIVE glass-incorporated light-curable pulp capping material. The study is aimed at evaluating the subcutaneous connective tissue reactions to MTA, Biodentine®, ACTIVA BioACTIVE Base/Liner. These materials were placed in polyethylene tubes and implanted into the dorsal connective tissue of Sprague Dawley rats. The presence of inflammation, predominant cell type, calcification, and thickness of fibrous connective tissue was recorded by histological examination 7, 30, and 60 days after the implantation procedure. Scores were defined as follows: 0 = none or few inflammatory cells, no reaction; 1 = <25 cells, mild reaction; 2 = 25 to 125 cells, moderate reaction; and 3 = ≥125 cells, severe reaction. Fibrous capsule thickness, necrosis, and formation of calcification were recorded. ANOVA and post hoc Dunnett's tests were used for statistically analyses (p < 0.05).Entities:
Year: 2020 PMID: 32518612 PMCID: PMC7254077 DOI: 10.1155/2020/6570159
Source DB: PubMed Journal: Scanning ISSN: 0161-0457 Impact factor: 1.932
The composition, batch number and manufacturers of dental materials.
| Product/batch/manufacturer | Composition |
|---|---|
| ACTIVA BioACTIVE Base/Liner | Blend of diurethane and other methacrylates with modified polyacrylic acid (∼53.2%), silica (∼3.0%), and sodium fluoride (∼0.9%) |
| ProRoot MTA | Tricalcium silicate (66.1%), dicalcium silicate (8.4%), tricalcium aluminate (2.0%), tetracalcium aluminoferrite, calcium sulphate bismuth oxide (14%), calcium oxide (8%), silicon oxide (0.5%), and aluminium oxide (1.0%) |
| Biodentine® | Powder: tricalcium silicate (80.1%), dicalcium silicate, calcium carbonate (14.9%), iron oxide, and zirconium oxide (5%). Liquid: water, calcium chloride, and partially modified polycarboxylate |
Number of samples with oedema, inflammation, fibrous capsule, calcification, and necrosis scores on days 7, 30, and 60.
| Control | ACTIVA BioACTİVE Base/Liner | ProRoot MTA | Biodentine® | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | |
| 7 days | Calcification | 7 | — | 4 | 3 | 5 | 2 | 5 | 2 | ||||||||
| Necrosis | 7 | — | 7 | — | 7 | — | 7 | — | |||||||||
| Oedema | 2 | 5 | — | — | — | 7 | — | — | 5 | 1 | 1 | — | — | 7 | — | — | |
| Inflammation | 0 | 5 | 2 | — | — | 1 | 5 | 1 | 1 | 5 | 1 | — | 4 | 3 | — | ||
| Fibrous capsule | 7 | — | 3 | 4 | 3 | 4 | 1 | 6 | |||||||||
| 30 days | Calcification | 7 | — | 4 | 3 | — | 7 | 2 | 5 | ||||||||
| Necrosis | 7 | — | 7 | — | 7 | — | 7 | — | |||||||||
| Oedema | 7 | — | — | — | 4 | 3 | 4 | 3 | 7 | ||||||||
| Inflammation | 5 | 2 | — | — | 1 | 6 | 3 | 4 | 4 | 3 | |||||||
| Fibrous capsule | — | 7 | — | 7 | — | 7 | — | 7 | |||||||||
| 60 days | Calcification | 7 | — | 2 | 5 | — | 7 | 2 | 5 | ||||||||
| Necrosis | 7 | — | 7 | — | 7 | — | 7 | — | |||||||||
| Oedema | 7 | — | — | — | 4 | 3 | — | — | 5 | 2 | — | — | 7 | — | — | — | |
| Inflammation | 7 | — | — | — | 5 | 2 | — | — | 6 | 1 | — | — | 6 | 1 | — | — | |
| Fibrous capsule | — | 7 | — | 7 | — | 7 | — | 7 | |||||||||
Oedema (0 = absent, 1 = mild, 2 = moderate, and 3 = severe), inflammatory response (0 = absent, 1 = mild, 2 = moderate, and 3 = severe), fibrous capsule (1 = thin at <150 μm and 2 = thick at >150 μm), calcification (0 = absent and 1 = present), and necrosis (0 = absent and 1 = present).
Figure 1Photomicrograph of H&E staining showing the subcutaneous tissue of the control (A), Biodentine® (B), ProRoot MTA (C), and ACTIVA BioACTİVE Base/Liner (D) after 7 days exposure. (a) Oedema, (b) inflammation, (c) fibrous capsule, and (d) calcification. (a) Mild oedema especially around the fibrous capsule areas was observed in all groups (H&E ×200). (b) Loose connective tissue and mild inflammation limited to the tube end, and giant cells were present in all groups (H&E ×200 and ×400). (c) Thin fibrous capsule formation was observed in all groups (H&E ×40). (d) Dystrophic calcification was observed around and inside the fibrous capsule in the Biodentine® (B), ProRoot MTA (C), and ACTIVA BioACTİVE Base/Liner (D) groups. No calcification was seen in the control group (H&E x 200).
Figure 2Photomicrograph of H&E staining showing the subcutaneous tissue of the control (A), Biodentine® (B), ProRoot MTA (C), and ACTIVA BioACTİVE Base/Liner (D) after 30 days exposure. (a) Oedema, (b) inflammation, (c) fibrous capsule, and (d) calcification. (a) Oedema was observed especially around the fibrous capsule in the ProRoot MTA (C) and ACTIVA BioACTİVE Base/Liner (D) groups (H&E ×100). (b) Loose connective tissue and mild inflammation were present in all groups around the fibrous capsule (H&E ×200). (c) Fibrous capsule formation was observed in all groups (H&E ×40). (d) Dystrophic calcification was observed around and inside the fibrous capsule in the Biodentine® (B), ProRoot MTA (C), and ACTIVA BioACTİVE Base/Liner (D) groups. No calcification was seen in the control group (H&E ×200).
Figure 3Photomicrograph of H&E staining showing the subcutaneous tissue of the control (A), Biodentine® (B), ProRoot MTA (C), and ACTIVA BioACTİVE Base/Liner (D) after 60 days exposure. (a) Oedema, (b) inflammation, (c) fibrous capsule, and (d) calcification. (a) Oedema was present especially around the fibrous capsule in the ProRoot MTA (C) and ACTIVA BioACTİVE Base/Liner (D) groups (H&E ×40). (b) Loose connective tissue and mild inflammation were observed around the fibrous capsule in the Biodentine® (B), ProRoot MTA (C), and ACTIVA BioACTİVE Base/Liner (D) groups. No inflammation was present in the control group (H&E ×100 and ×200). (c) Fibrous capsule formation was present in all groups (H&E ×40). (d) Dystrophic calcification was observed around and inside the fibrous capsule in Biodentine® (B), ProRoot MTA (C), and ACTIVA BioACTİVE Base/Liner (D) groups. No calcification was seen in the control group (H&E ×200).
Mean and standard deviation cell values of groups in all test periods.
| Groups | Mean ± SD | |||
|---|---|---|---|---|
| 7 days | 30 days | 60 days | ||
| Control | Calcification | 0.00 ± 0.000 | 0.00 ± 0.000 A | 0.00 ± 0.000 A |
| Necrosis | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 | |
| Oedema | 0.71 ± 0.488 | 0.00 ± 0.000 | 0.00 ± 0.000 | |
| Inflammation | 1.29 ± 0.488 | 0.29 ± 0.488 | 0.00 ± 0.000 | |
| Fibrous capsule | 1.00 ± 0.000 | 1.00 ± 0.000 | 1.00 ± 0.000 | |
| ACTIVA BioACTIVE Base/Liner | Calcification | 0.43 ± 0.535 | 0.43 ± 0.535 A | 0.71 ± 0.488 B |
| Necrosis | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 | |
| Oedema | 1.00 ± 0.000 | 0.43 ± 0.535 | 0.43 ± 0.535 | |
| Inflammation | 2.00 ± 0.577 | 0.86 ± 0.378 | 0.29 ± 0.488 | |
| Fibrous capsule | 0.57 ± 0.535 | 1.00 ± 0.000 | 1.00 ± 0.000 | |
| ProRoot MTA | Calcification | 0.29 ± 0.488 | 1.00 ± 0.000 B | 1.00 ± 0.000 B |
| Necrosis | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 | |
| Oedema | 1.00 ± 0.577 | 0.43 ± 0.535 | 0.29 ± 0.488 | |
| Inflammation | 2.00 ± 0.577 | 0.57 ± 0.535 | 0.14 ± 0.378 | |
| Fibrous capsule | 0.57 ± 0.535 | 1.00 ± 0.000 | 1.00 ± 0.000 | |
| Biodentine® | Calcification | 0.29 ± 0.488 | 0.71 ± 0.488 B | 0.71 ± 0.488 B |
| Necrosis | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 | |
| Oedema | 1.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 | |
| Inflammation | 1.43 ± 0.535 | 0.43 ± 0.535 | 0.14 ± 0.378 | |
| Fibrous capsule | 0.86 ± 0.378 | 1.00 ± 0.000 | 0.86 ± 0.378 | |
There is no difference between the same letters in the same column.